Stock listing
KRX:950130 Access Bio, Inc. (엑세스바이오) 주가
Follow Access Bio, Inc. into a list and get an email when it puts out news.
Share price · KRX:950130
₩1,689.00 KRW +32.00 (+1.9%)
Close on Nov 20, 2026
- Day range
- ₩1,652.00 – ₩1,724.00 KRWNov 20, 2026
- Volume
- 13,470 sharesNov 20, 2026
- Market cap
- ₩59.41B KRWAt the close on Nov 20, 2026 · price × 35.17M shares outstanding
- 52-week range
- ₩1,601.00 – ₩4,705.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩273.5M KRWMedian day 49,750 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:950130 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩1,689.00 | +32.00 | +1.9% | ₩1,708.00 | ₩1,724.00 | ₩1,652.00 | 13,470 | |
| ₩1,657.00 | +42.00 | +2.6% | ₩1,630.00 | ₩1,680.00 | ₩1,612.00 | 23,628 | |
| ₩1,615.00 | -26.00 | -1.6% | ₩1,605.00 | ₩1,714.00 | ₩1,605.00 | 18,817 | |
| ₩1,641.00 | -78.00 | -4.5% | ₩1,778.00 | ₩1,778.00 | ₩1,601.00 | 34,466 | |
| ₩1,719.00 | -26.00 | -1.5% | ₩1,730.00 | ₩1,799.00 | ₩1,711.00 | 32,286 | |
| ₩1,745.00 | -35.00 | -2.0% | ₩1,763.00 | ₩1,810.00 | ₩1,743.00 | 37,216 | |
| ₩1,780.00 | +9.00 | +0.5% | ₩1,772.00 | ₩1,809.00 | ₩1,760.00 | 41,155 | |
| ₩1,771.00 | -32.00 | -1.8% | ₩1,790.00 | ₩1,830.00 | ₩1,765.00 | 42,072 | |
| ₩1,803.00 | -29.00 | -1.6% | ₩1,810.00 | ₩1,836.00 | ₩1,783.00 | 27,960 | |
| ₩1,832.00 | +7.00 | +0.4% | ₩1,781.00 | ₩1,836.00 | ₩1,744.00 | 43,809 | |
| ₩1,825.00 | -75.00 | -3.9% | ₩1,870.00 | ₩1,917.00 | ₩1,825.00 | 17,124 | |
| ₩1,900.00 | +62.00 | +3.4% | ₩1,910.00 | ₩1,923.00 | ₩1,793.00 | 50,871 | |
| ₩1,838.00 | -73.00 | -3.8% | ₩1,944.00 | ₩1,945.00 | ₩1,836.00 | 30,597 | |
| ₩1,911.00 | -13.00 | -0.7% | ₩1,915.00 | ₩1,927.00 | ₩1,880.00 | 37,635 | |
| ₩1,924.00 | +4.00 | +0.2% | ₩1,920.00 | ₩1,970.00 | ₩1,857.00 | 25,494 | |
| ₩1,920.00 | -40.00 | -2.0% | ₩1,999.00 | ₩1,999.00 | ₩1,920.00 | 19,502 | |
| ₩1,960.00 | +37.00 | +1.9% | ₩1,935.00 | ₩1,970.00 | ₩1,920.00 | 31,057 | |
| ₩1,923.00 | +5.00 | +0.3% | ₩1,907.00 | ₩1,969.00 | ₩1,860.00 | 20,214 | |
| ₩1,918.00 | -41.00 | -2.1% | ₩1,921.00 | ₩1,980.00 | ₩1,777.00 | 45,605 | |
| ₩1,959.00 | -1.00 | -0.1% | ₩1,951.00 | ₩1,961.00 | ₩1,850.00 | 73,175 | |
| ₩1,960.00 | -70.00 | -3.4% | ₩2,030.00 | ₩2,030.00 | ₩1,951.00 | 98,329 | |
| ₩2,030.00 | -50.00 | -2.4% | ₩2,080.00 | ₩2,180.00 | ₩2,020.00 | 113,737 | |
| ₩2,080.00 | +70.00 | +3.5% | ₩2,045.00 | ₩2,490.00 | ₩2,045.00 | 1,044,511 | |
| ₩2,010.00 | +5.00 | +0.2% | ₩1,990.00 | ₩2,020.00 | ₩1,978.00 | 61,226 | |
| ₩2,005.00 | 0.00 | 0.0% | ₩1,971.00 | ₩2,070.00 | ₩1,971.00 | 40,203 | |
| ₩2,005.00 | -80.00 | -3.8% | ₩2,140.00 | ₩2,140.00 | ₩1,970.00 | 84,108 | |
| ₩2,085.00 | +45.00 | +2.2% | ₩2,040.00 | ₩2,145.00 | ₩2,040.00 | 27,769 | |
| ₩2,040.00 | -120.00 | -5.6% | ₩2,170.00 | ₩2,170.00 | ₩2,030.00 | 124,705 | |
| ₩2,160.00 | -80.00 | -3.6% | ₩2,255.00 | ₩2,260.00 | ₩2,160.00 | 43,352 | |
| ₩2,240.00 | -110.00 | -4.7% | ₩2,345.00 | ₩2,345.00 | ₩2,220.00 | 87,638 | |
| ₩2,350.00 | +165.00 | +7.6% | ₩2,255.00 | ₩2,480.00 | ₩2,220.00 | 498,625 | |
| ₩2,185.00 | +10.00 | +0.5% | ₩2,170.00 | ₩2,230.00 | ₩2,165.00 | 31,992 | |
| ₩2,175.00 | -15.00 | -0.7% | ₩2,190.00 | ₩2,200.00 | ₩2,120.00 | 49,447 | |
| ₩2,190.00 | +70.00 | +3.3% | ₩2,120.00 | ₩2,210.00 | ₩2,115.00 | 53,888 | |
| ₩2,120.00 | -50.00 | -2.3% | ₩2,280.00 | ₩2,280.00 | ₩2,100.00 | 178,208 | |
| ₩2,170.00 | -60.00 | -2.7% | ₩2,185.00 | ₩2,300.00 | ₩2,140.00 | 56,473 | |
| ₩2,230.00 | +25.00 | +1.1% | ₩2,230.00 | ₩2,325.00 | ₩2,220.00 | 46,532 | |
| ₩2,205.00 | +5.00 | +0.2% | ₩2,180.00 | ₩2,270.00 | ₩2,175.00 | 20,616 | |
| ₩2,200.00 | -15.00 | -0.7% | ₩2,225.00 | ₩2,270.00 | ₩2,100.00 | 77,393 | |
| ₩2,215.00 | -100.00 | -4.3% | ₩2,320.00 | ₩2,340.00 | ₩2,215.00 | 219,602 | |
| ₩2,315.00 | -135.00 | -5.5% | ₩2,470.00 | ₩2,470.00 | ₩2,285.00 | 166,750 | |
| ₩2,450.00 | -20.00 | -0.8% | ₩2,495.00 | ₩2,500.00 | ₩2,430.00 | 44,051 | |
| ₩2,470.00 | +20.00 | +0.8% | ₩2,500.00 | ₩2,500.00 | ₩2,410.00 | 28,484 | |
| ₩2,450.00 | -20.00 | -0.8% | ₩2,475.00 | ₩2,480.00 | ₩2,440.00 | 45,688 | |
| ₩2,470.00 | -5.00 | -0.2% | ₩2,430.00 | ₩2,545.00 | ₩2,430.00 | 96,497 | |
| ₩2,475.00 | +25.00 | +1.0% | ₩2,450.00 | ₩2,480.00 | ₩2,405.00 | 44,887 | |
| ₩2,450.00 | -45.00 | -1.8% | ₩2,500.00 | ₩2,500.00 | ₩2,400.00 | 46,331 | |
| ₩2,495.00 | +35.00 | +1.4% | ₩2,460.00 | ₩2,495.00 | ₩2,395.00 | 72,942 | |
| ₩2,460.00 | +5.00 | +0.2% | ₩2,460.00 | ₩2,510.00 | ₩2,415.00 | 69,335 | |
| ₩2,455.00 | -75.00 | -3.0% | ₩2,530.00 | ₩2,570.00 | ₩2,455.00 | 121,512 | |
| ₩2,530.00 | +5.00 | +0.2% | ₩2,525.00 | ₩2,570.00 | ₩2,460.00 | 50,053 | |
| ₩2,525.00 | +15.00 | +0.6% | ₩2,505.00 | ₩2,560.00 | ₩2,440.00 | 80,395 | |
| ₩2,510.00 | -60.00 | -2.3% | ₩2,570.00 | ₩2,650.00 | ₩2,425.00 | 99,316 | |
| ₩2,570.00 | 0.00 | 0.0% | ₩2,575.00 | ₩2,585.00 | ₩2,430.00 | 135,245 | |
| ₩2,570.00 | +45.00 | +1.8% | ₩2,570.00 | ₩2,640.00 | ₩2,395.00 | 270,145 | |
| ₩2,525.00 | +165.00 | +7.0% | ₩2,385.00 | ₩2,665.00 | ₩2,370.00 | 723,610 | |
| ₩2,360.00 | -5.00 | -0.2% | ₩2,365.00 | ₩2,375.00 | ₩2,315.00 | 60,395 | |
| ₩2,365.00 | 0.00 | 0.0% | ₩2,365.00 | ₩2,410.00 | ₩2,280.00 | 91,947 | |
| ₩2,365.00 | -40.00 | -1.7% | ₩2,350.00 | ₩2,400.00 | ₩2,290.00 | 221,830 | |
| ₩2,405.00 | +150.00 | +6.7% | ₩2,480.00 | ₩2,725.00 | ₩2,360.00 | 1,271,747 | |
| ₩2,255.00 | -65.00 | -2.8% | ₩2,350.00 | ₩2,350.00 | ₩2,190.00 | 37,812 | |
| ₩2,320.00 | +125.00 | +5.7% | ₩2,210.00 | ₩2,385.00 | ₩2,210.00 | 53,888 |
- Ticker
- KRX:950130
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- KRX
- Currency
- KRW
Access Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
Valuation
EV/sales −10.8× against a median of 2.2×: the lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −₩257.0B KRW
- P/E
- Loss
- EV/sales
- −10.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.1×
- Gross margin
- −133.5%
- Operating margin
- −296.7%
- Net margin
- −468.1%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Access Bio, Inc. · KRX:950130 | US$44.15M | −US$191.0M | n/a | −10.8× | n/a | 0.1× | −468.1% | 0.0× | n/a |
| Celemics, Inc. · KRX:331920 | US$49.19M | US$32.45M | n/a | 8.4× | n/a | 2.2× | −260.9% | 0.5× | n/a |
| Lumos Diagnostics Holdings Ltd. · ASX:LDX | US$47.13M | US$37.64M | n/a | 2.8× | n/a | 2.1× | −37.5% | 0.3× | n/a |
| Renalytix PLC · LSE:RENX | US$45.66M | US$45.26M | n/a | 15.1× | n/a | n/a | −680.0% | n/a | n/a |
| Labiana Health SA · BME:LAB | US$44.35M | US$70.57M | 15.7× | 0.9× | 5.8× | 8.0× | 3.4% | 5.9× | n/a |
| EDX Medical Group plc · LSE:EDX | US$43.78M | US$39.96M | n/a | 92.3× | n/a | 15.4× | n/a | 0.0× | n/a |
| Osang Healthcare Co. Ltd. · KRX:036220 | US$42.35M | US$24.18M | n/a | 0.3× | n/a | 0.2× | −8.8% | 0.1× | n/a |
| ABL Diagnostics SA · EURONEXT:ABLD | US$41.27M | US$42.32M | 38.1× | 5.5× | 42.8× | 5.3× | 14.2% | 0.3× | n/a |
| hVIVO plc · LSE:HVO | US$41.02M | US$42.24M | n/a | 0.7× | 7.5× | 1.0× | −12.8% | 0.4× | n/a |
| Harvard Bioscience, Inc. · NASDAQ:HBIO | US$39.60M | US$71.90M | n/a | 0.8× | 28.4× | 7.8× | −13.2% | 7.3× | 1.34 |
| CytoGen, Inc. · KRX:217330 | US$38.58M | US$31.66M | n/a | 1.6× | n/a | 1.6× | −38.5% | 0.4× | n/a |
| Median of the others | US$43.06M | US$41.10M | 26.9× | 2.2× | 18.0× | 2.2× | −13.2% | 0.4× | 1.34 |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.3B | 82.5M | 267.1M | 800.2M | 441.4M | 103.2M | 36.9M | 36.6M | 26.1M | 28.0M |
| Cost of revenue | 55.7B | 43.1M | 136.6M | 165.7M | 95.0M | 26.3M | 28.9M | 22.4M | 18.0M | 15.9M |
| Gross profit | -24.4B | 39.3M | 130.4M | 634.5M | 346.4M | 76.9M | 8.07M | 14.2M | 8.09M | 12.1M |
| Research and development | 8.48B | 10.8B | 16.1B | 7.32B | 4.89B | 4.01B | ||||
| Selling, general and administrative | 14.1B | 33.3M | 100.4M | 264.7M | 114.0M | 14.3M | 12.1M | 14.3M | 11.5M | 10.8M |
| Operating income | -63.3B | -4.12M | 18.0M | 363.1M | 227.1M | 55.8M | -13.9M | -4.58M | -6.45M | -601.2K |
| Depreciation and amortization | 17.2B | 13.4M | 12.1M | 8.28M | 4.83M | 3.41B | 3.42B | 3.07B | 2.53B | 1.51M |
| EBITDA | -46.1B | 9.30M | 30.2M | 371.4M | 232.0M | 3.47B | 3.41B | 3.07B | 2.53B | 912.4K |
| Interest expense | 2.32B | 3.47B | 3.71B | 6.23B | 3.35B | 1.87B | 0 | 0 | 0 | 0 |
| Income before tax | -105.4B | -105.5K | -4.50M | 358.9M | 224.4M | 52.9M | -18.5M | -5.58M | -9.33M | -49.9K |
| Income tax | 14.7B | -955.3M | 243.8M | -1.35B | ||||||
| Net income | -82.1B | -254.8K | -2.43M | 268.3M | 165.8M | 40.9M | -15.1M | -3.85M | -5.74M | 262.1K |
| Earnings per share, basic | -2,334.64 | -0.01 | -0.07 | 7.90 | 4.66 | 1.15 | -0.46 | -0.15 | -0.22 | 0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 323.3B | 232.8M | 277.6B | 7.53K | 3.90K | 45.2M | 5.90M | 4.59M | 5.46M | 5.90K |
| Short-term investments | 79.7B | 76.6M | 69.4B | 20.1M | 1.05M | 1.04M | 1.02M | 4.50M | 933.9K | 4.17M |
| Receivables | 2.44B | 5.27M | 17.8B | 91.2B | 54.6B | 27.5B | 5.90B | 13.6B | 10.5B | 11.5M |
| Inventory | 10.7B | 16.0M | 32.2B | 90.1M | 46.0M | 28.0B | 8.10B | 12.1B | 12.2B | 7.27M |
| Current assets | 433.3B | 340.3M | 418.4B | 564.8M | 276.8M | 111.9B | 25.9B | 40.5B | 35.3B | 48.6M |
| Property, plant and equipment | 93.3M | 108.2M | 103.0M | 68.0M | 49.1B | 30.9B | 30.4B | 31.4B | 25.3M | |
| Goodwill | 0 | 380.0K | 787.0K | 821.3K | 728.1K | |||||
| Total assets | 607.9B | 504.0M | 691.1B | 698.7M | 372.8M | 156.4M | 60.2M | 84.8M | 87.2M | 91.2M |
| Accounts payable | 612.8M | 1.15B | 3.46B | 2.20B | 9.74B | 4.73B | 1.46B | 2.68B | 737.9M | |
| Current liabilities | 24.9B | 27.5M | 44.0B | 154.9M | 116.6M | 69.6B | 17.7B | 23.2B | 17.2B | 2.41M |
| Long-term debt | 0 | 14.7B | 11.7M | 0 | 140.4K | 18.6M | 21.6M | 17.2M | 23.9M | |
| Total debt | 34.9M | 21.0M | 23.8M | 18.1M | 24.1M | |||||
| Total liabilities | 49.5B | 61.7M | 104.0B | 211.0M | 131.1M | 79.5M | 39.0M | 51.4M | 46.0M | 43.7M |
| Shareholders' equity | 557.2B | 442.3M | 584.2B | 487.7M | 241.7M | 76.9M | 21.2M | 33.4M | 41.1M | 47.5M |
| Shares outstanding | 35.2M | 35.2M | 33.8M | 34.0M | 35.6M | 35.6M | 32.8M | 26.3M | 26.3M | 26.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29.2B | 13.5M | -80.6M | 291.3M | 137.9M | 36.7B | -422.2M | -5.73B | -5.45B | 2.11M |
| Capital spending | -1.79B | -1.40M | -14.4M | -14.9M | -28.8M | -10.4B | -3.05B | -1.67B | -4.20B | -10.0M |
| Free cash flow | -31.0B | 17.9B | -122.6B | 350.3B | 129.4B | 26.0B | -6.39B | -7.40B | -9.65B | -7.91M |
| Cash from investing | 11.9M | -36.1M | -29.8M | -29.5M | -8.81B | 3.19B | -4.87B | -11.6B | -9.74M | |
| Cash from financing | -5.14M | -41.9M | -53.2M | 15.2M | 15.3B | -707.5M | 8.65B | 1.71B | 23.1M | |
| Dividends paid | 0 | -22.8M | ||||||||
| Share buybacks | 0 | -1.83M | -22.1M | 12.7K | 259.6K | 8.57M | -2.16M | -1.05M | ||
| Change in cash | -10.7B | 17.5M | -158.1M | 205.5M | 122.7M | 42.8B | 1.50B | -2.09B | -15.4B | 14.9M |
Cap table
Built by 6ix from Access Bio, Inc.’s releases
- Common shares
- 35,173,834
- Fully diluted
- 35,173,834
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 35,173,834 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 35,173,834 |
Log in to ask 6ix AI your own questions about Access Bio, Inc.